-
Greater availability of Plan B to boost sales
Sales of OTC female contraceptives ought to be significant in the coming year. Already, the category is up 2.3% to $232.7 million, and that number is expected to go up now that the Food and Drug Administration has approved Teva Women’s Health’s Plan B One-Step (levonorgestrel) without a prescription.